Multiple myeloma has been a notoriously difficult blood cancer to manage. Relapses are common despite the advances that have been made in treatments over the years. Idecabtagene vicleucel (Ide-cel) a new chimeric antigen receptor (CAR) T-cell therapy, has just been approved by the FDA for relapsed refractory multiple myeloma. This is the first CAR T-cell … Continued
For anyone living with a blood cancer, chimeric antigen receptor T-cell therapy (CAR-T) is a lifeline. Leukaemia and lymphoma patients who have exhausted all other treatment options are given another chance at life. Their own immune system T-cells are genetically engineered to recognise cancer cells and destroy them. It is expected that the demand for … Continued
Myeloma is currently known as a terminal blood cancer. There is no cure, however there are many new treatments on the horizon which show great promise. Clinical trials are the gateway to accessing these new treatments, but not all myeloma patients are created equal when it comes to clinical trial eligibility. Geoff Nyssen wants to … Continued
We are incredibly proud to share with you our 2020 Annual Review featuring financial highlights from 2019-2020. It was a year full of challenges, one that sharpened our focus on what is truly important and dear to us. We believe in our mission to accelerate next-generation treatments for Australian blood cancer patients to help them … Continued
For many patients access to a clinical trial can literally save their life. In speaking to The West Australian newspaper, Prof Chan Cheah told reporter Katie Hampson, when he trained in Melbourne and the U.S he had a range of trials he could put a patient on when they had exhausted all other options. These options … Continued
Clinical trials are often the gateway to new treatments for patients with blood cancer. When new therapies are being tested they go through various stages. If you have ever wondered about the various clinical trial stages and what they mean, below is a synopsis to provide you with some insight. Phase I trials are the … Continued
In the last six weeks the U.S. Food and Drug Administration (FDA) has approved five additional treatments for blood cancer. The rate at which new treatments are being approved in the U.S. is incredibly encouraging. It demonstrates the progress researchers are making in finding new and novel ways to treat cancer. It is also frustrating … Continued
Prof Miles Prince AM was devastated when back in 2018, his patient Tom Long had to embark on a journey to Seattle USA in order to receive chimeric antigen receptor T-cell (CAR T) therapy via a clinical trial. He knew that while Australia had the clinical expertise to administer CAR T-cell therapy, we did not … Continued
In June 2019, the U.S. FDA approved selinexor (Xpovio) in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Myeloma patients had to have been treated with at least four prior therapies. In November 2020, the results of the BOSTON study were published which demonstrated the benefits of using selinexor earlier in … Continued